Once daily (600 mg) administration:

12 Twice daily (300 mg) administration:

The dosing regimen consists of a 5-week initial phase followed by a maintenance phase:

The twice-daily dosing regimen of ivabradine gave uniform efficacy over 24 hours.

This dosing regimen for paediatric patients weighing 14-30 kg is based primarily on pharmacokinetic modelling.

This dosing regimen for paediatric patients weighing 14-30 kg is based primarily on pharmacokinetic modelling, with supporting data from clinical studies.

Once daily administration (abacavir 600 mg): the benefit of abacavir as a once daily regimen is mainly based on a study performed in combination with efavirenz and lamivudine, in antiretroviral- naïve adult patients (see section 5.1).

The once daily regimen of abacavir is supported by a 48 weeks multi-centre, double-blind, controlled study (CNA30021) of 770 HIV-infected, therapy-naïve adults.

The dosing regimen for paediatric patients weighing 14-30 kg is based primarily on pharmacokinetic modelling and supported by data from clinical studies using the individual components lamivudine and zidovudine.

Such studies are especially useful to assist the clinician in establishing dosage regimens (route and site of administration, dose, dosing interval, number of administrations, etc.) and to adopt dosage regimens according to certain population variables (e. g. age, disease).

use of these parameters to investigate the relationships between dosage regimen, plasma and tissue concentration and pharmacologic, therapeutic or toxic effects.

This dosage regimen should 12.5 mg/ day

The prescribed dosage regimen should be continued.

The dose and dosage regimen is dependent on the indication.

This dosage regimen should be used when the following are

Appropriate dose titration should be considered.

This dosage regimen should be used when the following are added

The 300 mg tablet is only suitable for the once a day regimen.

Posology The dose and dosage regimen is dependent on the indication.

The recommended dosing regimen is presented in Tables 1 and 2.

The appropriate dose regimen in patients with less severe hepatic impairment is unknown.

The following dosing regimen was used in study AC-052-356 (BREATHE-3):

The choice of positive control products and the dosing regiment applied were discussed:

0.15 mg/ kg/ day* 0.3 mg/ kg/ day 1 − (once a day) (once a day)

Preliminary clinical data suggest that CRIXIVAN 400 mg in

It is important that the dosage regimen of NovoSeven is compliant with the recommended dosage as stated in section 4.2.

15 The dose regimen of Mycamine depends on the body weight of the patient as given in the following tables:

An alternative dosing schedule for adults is CRIXIVAN 400 mg with ritonavir 100 mg both administered orally twice a day.

The recommended dosage regimen for galsulfase is 1 mg/ kg body weight administered once every week as an intravenous infusion over 4 hours.

Therefore 70 mg twice daily remains the recommended dose schedule in imatinib-resistant or intolerant patients with advanced phase CML and Ph+ALL.

Dosage The recommended dosage regimen of galsulfase is 1 mg/ kg body weight administered once every week as an intravenous infusion.

This dosage regimen should be used when other medicinal products that do not significantly inhibit or induce lamotrigine glucuronidation are withdrawn

ViraferonPeg monotherapy As monotherapy the ViraferonPeg regimen is 0.5 or 1.0 microgram/kg/week.

The recommended dosage regimen of Aldurazyme is 100 U/ kg body weight administered once every week as an intravenous infusion.

Your doctor will determine the exact dosage schedule and regimen according to your needs.

This dosage regimen should be used when other medicinal products that do not significantly inhibit or induce lamotrigine glucuronidation are added

The usual dosage regimen for Rapamune is a 6 mg oral loading dose, administered as soon as possible after transplantation, followed by 2 mg once daily.

These data were further substantiated by the supportive study APV20003; however, a different dosage regimen than that of study APV29005 was used.

from an efficacy and safety viewpoint, for the dosing regimen of 200-400 mg ciprofloxacin twice daily for the treatment of complicated UTI.

Children and adolescents aged 2 to 12 years - recommended treatment regimen in epilepsy (total daily dose in mg/ kg body weight/ day)

The proposed dosage regimen for complicated urinary tract infections (100 mg bid) was considered too low and should be changed to 200-400 mg twice daily.

Patients changing to the once daily regimen should take 300 mg twice a day and switch to 600 mg once a day the following morning.

Patients changing to the once daily regimen should take 300 mg (15 ml) twice a day and switch to 600 mg (30 ml) once a day the following morning.

Replacement therapy in primary immunodeficiency syndromes The dosage regimen should achieve a trough IgG level (measured before the next infusion) of at least 4 to 6 g/l.

2 back to a twice daily regimen, patients should complete the day 's treatment and start 300 mg twice a day the following morning.

Adjunctive therapy WITHOUT valproate and WITH inducers of lamotrigine glucuronidation (see section 4.5): This dosage regimen should be used without valproate but with:

Based on simulation data, an alternating daily dosing regimen of 800 mg and 400 mg in patients with severe renal impairment can approximate the AUC (0-48h) in healthy subjects receiving 800 mg once daily.

When changing back to a twice daily regimen, patients should complete the day 's treatment and start 300 mg (15 ml) twice a day the following morning.

When changing back to a twice daily regimen patients should complete the days treatment and start 150 mg twice a day the following morning.

ZYPADHERA is not recommended for treatment in the elderly population unless a well-tolerated and effective dosage regimen using oral olanzapine has been established.